Public engagement and clinical trials new models and disruptive technologies : workshop summary
Clinical trials provide essential information needed to turn basic medical research findings into patient treatments. New treatments must be studied in large numbers of humans to find out whether they are effective and to assess any harm that may arise from treatment. There is growing recognition am...
| Main Author: | |
|---|---|
| Corporate Authors: | , , |
| Other Authors: | , |
| Format: | eBook |
| Language: | English |
| Published: |
Washington, D.C.
National Academies Press
2012, c2012
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Clinical trials provide essential information needed to turn basic medical research findings into patient treatments. New treatments must be studied in large numbers of humans to find out whether they are effective and to assess any harm that may arise from treatment. There is growing recognition among many stakeholders that the U.S. clinical trials enterprise is unable to keep pace with the national demand for research results. The IOM, along with the Mount Sinai School of Medicine, held a workshop June 27-28, 2011, to engage stakeholders and experts in a discussion about possible solutions to improve public engagement in clinical trials |
|---|---|
| Physical Description: | xvi, 124 p. 1 col. ill. 23 cm |
| ISBN: | 0309219299 9780309219297 |